Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The company is assessing the situation and simultaneously undertaking all the requisite action
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
GMM Pfaudler US completes acquisition of MixPro
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
Subscribe To Our Newsletter & Stay Updated
